Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOPA: Neoadjuvant CRT vs Upfront Surgery in Pancreatic Cancer
NCT01900327Phase 3Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Feb 2014
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by University Medical Center Hamburg-Eppendorf. Started Feb 2014; status: terminated.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01900327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01900327.